檢索結果 - Michal Lotem

Refine Results
  1. 1
    COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma

    COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma 由 Mordechai Avner, Marina Orevi, Nadia Caplan, Aron Popovtzer, Michal Lotem, Jonathan Cohen

    出版 2021
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy

    Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy 由 Shay Tzaban, Otto Stern, Elad Zisman, Galit Eisenberg, Shiri Klein, Shoshana Frankenburg, Michal Lotem

    出版 2025
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

    Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma 由 Olga Lyass, Beatrice Uziely, Rami Ben‐Yosef, Dinah Tzemach, Norman I. Heshing, Michal Lotem, G Brufman, Alberto Gabizon

    出版 2000
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients

    Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients 由 Sivan, Sapoznik, Suzan, Faranesh, Rona, Ortenberg, Tamar, Hamburger, Vivian, Barak, Tamar, Peretz, Jacob, Schachter, Gal, Markel, Michal, Lotem

    出版 2012
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  5. 5
    Pathways and therapeutic targets in melanoma

    Pathways and therapeutic targets in melanoma 由 Emma Shtivelman, Michael A. Davies, Patrick Hwu, James C. Yang, Michal Lotem, Moshe Oren, Keith T. Flaherty, David E. Fisher

    出版 2014
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    The future of affordable cancer immunotherapy

    The future of affordable cancer immunotherapy 由 Niels Schaft, Jan Dörrie, Gerold Schuler, Beatrice Schuler‐Thurner, Husam Sallam, Shiri Klein, Galit Eisenberg, Shoshana Frankenburg, Michal Lotem, Areej Khatib

    出版 2023
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin

    The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein L... 由 Itay Lazar, Yaacov Barak, Tamar Shiloach, Elad Eliahoo, Luna Kadouri, Michal Lotem, Riki Perlman, Zichria Zakay‐Rones, Amos Panet, Dina Ben‐Yehuda

    出版 2009
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    CD66a Interactions Between Human Melanoma and NK Cells: A Novel Class I MHC-Independent Inhibitory Mechanism of Cytotoxicity

    CD66a Interactions Between Human Melanoma and NK Cells: A Novel Class I MHC-Independent Inhibitory Mechanism of Cytotoxicity 由 Gal Markel, Niva Lieberman, Gil Katz, Tal I. Arnon, Michal Lotem, Olga Drize, Richard S. Blumberg, Erez Bar‐Haim, Reuven Mader, Lea Eisenbach, Ofer Mandelboim

    出版 2002
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients

    Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients 由 Solange Peters, Verena Voelter, Léonidas Zografos, S. Pampallona, Răzvan Popescu, M Gillet, W. Bosshard, Giammaria Fiorentini, Michal Lotem, Rony Weitzen, Ulrich Keilholz, Yves Humblet, Sophie Piperno‐Neumann, Roger Stupp, Serge Leyvraz

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma

    Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma 由 Shelly Kalaora, Joo Sang Lee, Eilon Barnea, Ronen Levy, Polina Greenberg, Michal Alon, Gal Yagel, Gitit Bar Eli, Roni Oren, Aviyah Peri, Sushant Patkar, Lital Bitton, Steven A. Rosenberg, Michal Lotem, Yishai Levin, Arie Admon, Eytan Ruppin, Yardena Samuels

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    <i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment

    <i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment 由 Martino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj, Michal Shreberk‐Shaked, Ori Hassin, Saptaparna Mukherjee, Sharathchandra Arandkar, Ron Rotkopf, Abby Kapsack, Giuseppina Lambiase, Bianca Pellegrino, Eyal Ben-Isaac, Ofra Golani, Yoseph Addadi, Emma Hajaj, Raya Eilam, Ravid Straussman, Yosef Yarden, Michal Lotem, Moshe Oren

    出版 2021
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

    KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma 由 Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J. Diede, Elizabeth Croydon, Antoni Ribas, Paolo A. Ascierto

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

    KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma 由 Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Stephens, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study 由 Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Interferon-stimulated neutrophils as a predictor of immunotherapy response

    Interferon-stimulated neutrophils as a predictor of immunotherapy response 由 Madeleine Benguigui, Tim J. Cooper, Prajakta Kalkar, Sagie Schif‐Zuck, Ruth Halaban, Antonella Bacchiocchi, Iris Kamer, Abhilash Deo, Bar Manobla, Rotem Menachem, Jozafina Haj-Shomaly, Avital Vorontsova, Ziv Raviv, Chen Buxbaum, Petros Christopoulos, Jair Bar, Michal Lotem, Mario Sznol, Amiram Ariel, Shai S. Shen-Orr, Yuval Shaked

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

    PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR 由 Soma Ghosh, Nishanth Belugali Nataraj, Ashish Noronha, Sushant Patkar, Arunachalam Sekar, Saptaparna Mukherjee, Sabina Winograd‐Katz, Lior Kramarski, Aakanksha Verma, Moshit Lindzen, Diana Drago-García, Joseph Green, Galit Eisenberg, Hava Gil-Henn, Arkaprabha Basu, Yan Lender, Shimon Weiss, Moshe Oren, Michal Lotem, Benjamin Geiger, Eytan Ruppin, Yosef Yarden

    出版 2021
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Pembrolizumab versus Ipilimumab in Advanced Melanoma 由 Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Haiyu Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma 由 Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

    Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma 由 Shelly Kalaora, Yochai Wolf, Tali Feferman, Eilon Barnea, Erez Greenstein, Dan Reshef, Itay Tirosh, Alexandre Reuben, Sushant Patkar, Ronen Levy, Juliane Quinkhardt, Tana Omokoko, Nouar Qutob, Ofra Golani, Jianhua Zhang, Xizeng Mao, Xingzhi Song, Chantale Bernatchez, Cara Haymaker, Marie-Andrée Forget, Caitlin Creasy, Polina Greenberg, Brett W. Carter, Zachary A. Cooper, Steven A. Rosenberg, Michal Lotem, Uğur Şahin, Guy Shakhar, Eytan Ruppin, Jennifer A. Wargo, Nir Friedman, Arie Admon, Yardena Samuels

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

    Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer 由 Petros Christopoulos, Michal Harel, Kimberly McGregor, Yehuda Brody, Igor Puzanov, Jair Bar, Yehonatan Elon, Itamar Sela, Ben Yellin, Coren Lahav, Shani Raveh, Anat Reiner‐Benaim, Niels Reinmuth, Hovav Nechushtan, David Farrugia, Ernesto Bustinza-Linares, Yanyan Lou, Raya Leibowitz‐Amit, Iris Kamer, Alona Zer, Mor Moskovitz, Adva Levy‐Barda, Ina Koch, Michal Lotem, Rivka Katzenelson, Abed Agbarya, Gillian Price, Helen Cheley, Mahmoud Abu-Amna, T. Geldart, Maya Gottfried, Ella Tepper, Andreas Polychronis, Ido Wolf, Adam P. Dicker, David P. Carbone, David R. Gandara

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: